FDA approves Gilead's Hepcludex
Analysis based on 12 articles · First reported May 22, 2026 · Last updated May 26, 2026
The approval of Hepcludex by the United States — Food and Drug Administration>>> is expected to positively impact Gilead Sciences>>>' stock price due to its establishment as the first and only approved treatment for chronic hepatitis delta virus in the United States>>>. This creates a new revenue stream and strengthens Gilead Sciences>>>' position in the specialty viral disease market.
The United States — Food and Drug Administration>>> has granted accelerated approval to Gilead Sciences>>>' Hepcludex (bulevirtide-gmod) for the treatment of chronic hepatitis delta virus (HDV) infection in adults in the United States>>>. This marks the first approved therapy for HDV, a severe liver disease that occurs only in individuals with hepatitis B virus (HBV) and carries a high risk of liver complications and mortality. The approval is based on data from the Phase III MYR301 study, which demonstrated significant improvements in virologic and biochemical responses. While an improvement in long-term clinical outcomes is yet to be established, this approval addresses a critical unmet medical need for an estimated 40,000 to 80,000 people in the United States>>>. Gilead Sciences>>> has committed to a confirmatory long-term outcomes study.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard